Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation
Diabetes mellitus is a chronic illness that needs persistent medical attention and continuous patient self-management to avoid acute complications. Dipeptidyl peptidase-IV (DPP-IV) inhibitors minimize glucagon and blood glucose levels by increasing the incretin levels, glucagon-like peptide (GLP-1)...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Sciendo
2021-12-01
|
| Collection: | Acta Pharmaceutica |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.2478/acph-2021-0034 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|